Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

enVVeno Medical Corporation - Common Stock (NQ: NVNO )

2.870 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 2.870
Bid (Size) 2.300 (1)
Ask (Size) 3.710 (4)
Prev. Close 2.870
Today's Range 2.870 - 2.870
52wk Range 2.450 - 6.500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25
Via ACCESS Newswire
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Via ACCESS Newswire

Performance

YTD
-6.51%
-6.51%
1 Month
-5.90%
-5.90%
3 Month
-2.05%
-2.05%
6 Month
-45.12%
-45.12%
1 Year
-53.71%
-53.71%

More News

Read More
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum
Via ACCESS Newswire
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting
Via ACCESS Newswire
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe
Via ACCESSWIRE
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website
Via ACCESSWIRE
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium
Via ACCESSWIRE
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval
Via ACCESSWIRE
enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)
Via ACCESSWIRE
enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing
Via ACCESSWIRE
enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
BioMedNewsBreaks — enVVeno Medical Corporation (NASDAQ: NVNO) Announces Pricing of $15M Underwritten Public Offering
Via Investor Brand Network
Crude Oil Rises; Onconetix Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)
Via ACCESSWIRE
Nasdaq Moves Lower; Fed's Preferred Inflation Gauge Falls More Than Projected
Via Benzinga
Topics Economy
Exposures Interest Rates
Dow Surges Over 100 Points; Costco Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
Via Benzinga
enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
enVVeno Medical Corporation Announces Proposed Public Offering
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.